Forty-five patients with inoperable non small cell lung carcinoma were treated according to a sequential polychemotherapeutic regimen with cisplatin-vinblastine (A), cyclophosphamide-etoposide (B), and adriamycin-vincristine (C). Patients were evaluated every two cycles. Ten patients (22.2 %) showed a partial response with a mean duration of 20 weeks, and mean survival of 50.8 weeks. It is remarkable that, among them, 6 patients (13.3 %) lived over 12 months and three (6.6 %) over 18 months. The mean survival for all patients was 35.7 weeks. Toxicity was acceptable and reversible.
Get full access to this article
View all access options for this article.
References
1.
AisnerJ., WhitacreM., Van EchoD.A., WiernikP.H.: Combination chemotherapy for small cell carcinoma of the lung: continuous versus alternating non-cross-resistant combinations.Cancer Treat. Rep., 66 (2): 221–230, 1982.
2.
AlbhinK.S., BitranJ.D., GolombH.M., HoffmanP.C., DemeesterT.R., SkoseyC., NobleS., BloughR.R.: Trial of vindesine etoposide and cisplatin in patients with previously treated advanced stage non-small-cell bronchogenic carcinoma.Cancer Treat. Rep., 68 (2): 413–416, 1984.
KrisM.G., GrallaR.J., KalmanL.A., KelsenD.P., CasperE.S., BurkeM.T., GroshenS., CibasI.R., BaginR., HeelanR.T.: Randomized trial comparing vindesine plus cisplatin with vinblastine plus cisplatin in patients with non-small cell lung cancer, with an analysis of methods of response assessment.Cancer Treat. Rep., 69(4): 387–395, 1985.
8.
LindgrenD., CadmanE., ErichsonR., GrannV., SachsK.: Use of cisplatin, cyclophosphamide, vincristine, and doxorubicin for the treatment of non-small cell lung cancer.Cancer Treat. Rep., 68(9): 1159–1161, 1984.
9.
MarkmanM., PendergrassK.B., AbeloffM.D.: Intensive timed sequential combination chemotherapy in extensive-stage small cell carcinoma of the lung.Cancer Treat. Rep., 66(13): 1880, 1982.
10.
MorascaL., MarsoniS., Brambilla PisoniM., PiazzaE., VagoG., CasaliV., CogoR., BianchiC., ScapaticciR., LibrettiA.: VP16213 and cyclophosphamide in non oat cell bronchogenic carcinoma.Cancer Chemother. Pharmacol., 7: 209–210, 1982.
11.
SchulmanP., BudmanD.R., WeiselbergL., VinciguerraV., DegnanT.J.: Phase II trial of mitomycin, vinblastine, and cisplatin (MVP) in non-small cell bronchogenic carcinoma.Cancer Treat. Rep., 67 (13): 943–945, 1983.
12.
SculterJ.P., KlasterskyJ.: Progress in chemotherapy of non-small cell lung cancer.Eur. J. Cancer Clin. Oncol., 20 (11): 1329–1333, 1984.
13.
VoglS.E., KaplanB.H.: Chemotherapy of advanced head and neck cancer with methotrexate, bleomycin, and cis-diamminedichloroplatinum II in an effective outpatient schedule.Cancer, 44 (1): 26–31, 1979.
